About Taylor Copeland

This author has not yet filled in any details.
So far Taylor Copeland has created 7 blog entries.

Cadent Therapeutics Announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia

By |2019-05-30T11:48:23+00:00May 29th, 2019|

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAD-1883, an investigational treatment for spinocerebellar ataxia (SCA), a genetic disorder characterized by progressive loss of coordination...